Top

Gepubliceerd in:

20-05-2024

Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure

Auteurs: Jacqueline Jonklaas, Alaina L. Carr, George Luta, Chenlu Yu, Roxanne E. Jensen, Emma Reasner, Justin Winslow, Charlene C. Kuo, Bruce J. Davidson, Giuseppe Esposito, Gary Bloom, Samantha A. Diamond-Rossi, Kristi D. Graves

Gepubliceerd in: Quality of Life Research | Uitgave 7/2024

Abstract

Purpose

This study aimed to develop and psychometrically evaluate a patient-reported outcome measure (PROM), SAlivary, LAcrimal, NaSal (SALANS), to document patients’ symptoms after radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC).

Methods

We generated and iteratively revised SALANS items based on expert input, focus group discussions and feedback from cognitive testing (n = 17). We administered an initial SALANS measure with 39 items to patients diagnosed with DTC in the past two years (n = 105). Exploratory factor analysis (EFA) examined the factor structure of the SALANS items. We assessed the consistency reliability and related the total and subscale scores of the final SALANS to existing PROMs to assess validity.

Results

The final SALANS consisted of 33 items and six subscales (sialadenitis, taste, xerostomia, dry eyes, epiphora, and nasal) with six factors extracted by EFA. The six subscales demonstrated good internal reliability (α range = 0.87—0.92). The SALANS total score showed good convergent validity with the Xerostomia Inventory (r = 0.86) and good discriminant validity with a measure of spirituality (r = − 0.05). The mean SALANS total score was significantly higher (d = 0.5, p < 0.04) among patients who had RAI compared to those who did not have RAI.

Conclusion

Preliminary evidence suggests that SALANS is a novel and reliable PROM to assess the type and frequency all symptoms experienced after RAI treatment for DTC. Future work is needed to further validate and develop the scale.

vorige artikel Physician and informal care use explained by the Pediatric Quality of Life Inventory (PedsQL) in children with suspected genetic disorders

Alleen toegankelijk voor geautoriseerde gebruikers

Fard-Esfahani, A., Emami-Ardekani, A., Fallahi, B., Fard-Esfahani, P., Beiki, D., Hassanzadeh-Rad, A., & Eftekhari, M. (2014). Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. Nuclear Medicine Communications, 35(8), 808–817. https://doi.org/10.1097/MNM.0000000000000132CrossRefPubMed

Duan, H., Gamper, E., Becherer, A., & Hoffmann, M. (2015). Quality of life aspects in the management of thyroid cancer. Oral Oncology, 51(6), S1-5. https://doi.org/10.1016/j.oraloncology.2015.03.008CrossRefPubMed

Institute of Medicine & National Research Council. (2006). From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press. https://doi.org/10.17226/11468CrossRef

Levit, L. A., Balogh, E., Nass, S. J., & Ganz, P. (2013). Delivering high-quality cancer care: Charting a new course for a system in crisis. National Academies Press Washington.CrossRef

Caglar, M., Tuncel, M., & Alpar, R. (2002). Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clinical Nuclear Medicine, 27(11), 767–771.CrossRefPubMed

Esfahani, A. F., Fallahi, B., Olamaie, R., Eftekhari, M., Beiki, D., & Saghari, M. (2004). Semi-quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment. Hellenic Journal of Nuclear Medicine, 7(3), 206–209.PubMed

Nakada, K., Ishibashi, T., Takei, T., Hirata, K., Shinohara, K., Katoh, S., Zhao, S., Tamaki, N., Noguchi, Y., & Noguchi, S. (2005). Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? Journal of Nuclear Medicine, 46(2), 261–266.PubMed

Solans, R., Bosch, J.-A., Galofré, P., Porta, F., Roselló, J., Selva-O’Callagan, A., & Vilardell, M. (2001). Salivary and lacrimal gland dysfunction (Sicca Syndrome) after radioiodine therapy. Journal of Nuclear Medicine, 42(5), 738–743.PubMed

Thomson, W. M., Chalmers, J. M., Spencer, A. J., & Williams, S. M. (1999). The Xerostomia Inventory: A multi-item approach to measuring dry mouth. Community Dental Health, 16(1), 12–17.PubMed

10.

Bian, X., Song, T., & Wu, S. (2015). Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: Based on the EORTC QLQ-C30 and H&N35 questionnaires. Expert Review of Anticancer Therapy, 15(1), 109–119. https://doi.org/10.1586/14737140.2015.961427CrossRefPubMed

11.

Eisbruch, A., Kim, H. M., Terrell, J. E., Marsh, L. H., Dawson, L. A., & Ship, J. A. (2001). Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 50(3), 695–704. https://doi.org/10.1016/S0360-3016(01)01512-7CrossRefPubMed

12.

Bowman, S. J., Booth, D. A., Platts, R. G., Field, A., Rostron, J., UK Sjögren’s Interest Group. (2003). Validation of the Sicca symptoms inventory for clinical studies of Sjögren’s syndrome. The Journal of Rheumatology, 30(6), 1259–1266.PubMed

13.

Sherman, A. C., Simonton, S., Adams, D. C., Vural, E., Owens, B., & Hanna, E. (2000). Assessing quality of life in patients with head and neck cancer: Cross-validation of the European organization for research and treatment of cancer (EORTC) quality of life head and neck module (QLQ-H&N35). Archives of Otolaryngology-Head & Neck Surgery, 126(4), 459–467. https://doi.org/10.1001/archotol.126.4.459CrossRef

14.

Bjordal, K., Hammerlid, E., Ahlner-Elmqvist, M., de Graeff, A., Boysen, M., Evensen, J., Biörklund, A., Leeuw, R., Fayers, P., Jannert, M., Westin, T., & Kaasa, S. (1999). Quality of life in head and neck cancer patients: Validation of the european organization for research and treatment of cancer quality of life questionnaire-H&N35. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 17, 1008–1019. https://doi.org/10.1200/JCO.1999.17.3.1008CrossRefPubMed

15.

Verdonck-de Leeuw, I. M., Buffart, L. M., Heymans, M. W., Rietveld, D. H., Doornaert, P., de Bree, R., Buter, J., Aaronson, N. K., Slotman, B. J., Leemans, C. R., & Langendijk, J. A. (2014). The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: A prospective cohort study. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 110(3), 422–428. https://doi.org/10.1016/j.radonc.2014.01.002CrossRefPubMed

16.

Seror, R., Theander, E., Bootsma, H., Bowman, S. J., Tzioufas, A., Gottenberg, J.-E., Ramos-Casals, M., Dörner, T., Ravaud, P., Mariette, X., & Vitali, C. (2014). Outcome measures for primary Sjögren’s syndrome: A comprehensive review. Journal of Autoimmunity, 51, 51–56. https://doi.org/10.1016/j.jaut.2013.12.010CrossRefPubMed

17.

Thomson, W. M. (2007). Measuring change in dry-mouth symptoms over time using the Xerostomia Inventory. Gerodontology, 24(1), 30–35. https://doi.org/10.1111/j.1741-2358.2007.00137.xCrossRefPubMed

18.

Gulati, A., Kidane, J., & Chang, J. L. (2023). Patient reported outcome measures for salivary function: A systematic review. The Laryngoscope. https://doi.org/10.1002/lary.30550CrossRefPubMed

19.

Bhayani, M. K., Acharya, V., Kongkiatkamon, S., Farah, S., Roberts, D. B., Sterba, J., Chambers, M. S., & Lai, S. Y. (2015). Sialendoscopy for patients with radioiodine-induced sialadenitis and xerostomia. Thyroid, 25(7), 834–838.CrossRefPubMedPubMedCentral

20.

La Perle, K. M., Kim, D. C., Hall, N. C., Bobbey, A., Shen, D. H., Nagy, R. S., Wakely, P. E., Jr., Lehman, A., Jarjoura, D., & Jhiang, S. M. (2013). Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid, 23(8), 1029–1036.CrossRefPubMedPubMedCentral

21.

Gning, I., Trask, P. C., Mendoza, T. R., Harle, M. T., Gutierrez, K. A., Kitaka, S. A., Sherman, S. I., & Cleeland, C. S. (2009). Development and initial validation of the thyroid cancer module of the MD anderson symptom inventory. Oncology, 76(1), 59–68.CrossRefPubMed

22.

Husson, O., Haak, H. R., Buffart, L. M., Nieuwlaat, W.-A., Oranje, W. A., Mols, F., Kuijpens, J. L., Coebergh, J. W., & van de Poll-Franse, L. V. (2013). Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: A study from the population-based PROFILES registry. Acta Oncologica, 52(2), 249–258.CrossRefPubMed

23.

Husson, O., Haak, H. R., Mols, F., Nieuwenhuijzen, G. A., Nieuwlaat, W.-A., Reemst, P. H., Huysmans, D. A., Toorians, A. W., & van de Poll-Franse, L. V. (2013). Development of a disease-specific health-related quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors. Acta Oncologica, 52(2), 447–454. https://doi.org/10.3109/0284186X.2012.718445CrossRefPubMed

24.

Buchholzer, S., Thakachy Subha, S., Tchérémissinoff, L., Boselie, F., Triponez, F., Faure, F., Lopez, J.-M., Borner, U., Kleinjung, T., Seebach, J. D., Dulguerov, P., & Marchal, F. (2021). The RAI-6 questionnaire: A new screening questionnaire to monitor complications of radioiodine treatment. Frontiers in Surgery. https://doi.org/10.3389/fsurg.2021.641945CrossRefPubMedPubMedCentral

25.

Le Roux, M., Graillon, N., Guyot, L., Taieb, D., Galli, P., Godio-Raboutet, Y., Chossegros, C., & Foletti, J. (2020). Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study. Head & Neck, 42(11), 3133–3140.CrossRef

26.

Kim, Y., Choi, J., Hong, S. B., Hyun, I. Y., & Lim, J. (2016). Salivary gland function after sialendoscopy for treatment of chronic radioiodine-induced sialadenitis. Head & Neck, 38(1), 51–58.CrossRef

27.

Moreddu, E., Baumstarck-Barrau, K., Gabriel, S., Fakhry, N., Sebag, F., Mundler, O., Chossegros, C., & Taïeb, D. (2017). Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire. British Journal of Oral and Maxillofacial Surgery, 55(6), 609–612. https://doi.org/10.1016/j.bjoms.2017.03.019CrossRefPubMed

28.

Baudin, C., Bressand, A., Buffet, C., Menegaux, F., Soret, M., Lê, A. T., Cardon, T., Broggio, D., Bassinet, C., Huet, C., Armengol, G., Richardson, D. B., Leenhardt, L., Bernier, M.-O., & Lussey-Lepoutre, C. (2023). Dysfunction of the salivary and lacrimal glands after radioiodine therapy for thyroid cancer: Results of the START study after 6-months of follow-up. Thyroid. https://doi.org/10.1089/thy.2023.0090CrossRefPubMed

29.

Singer, S., Al-Ibraheem, A., Pinto, M., Iakovou, I., Østhus, A. A., Hammerlid, E., Locati, L. D., Gamper, E., Ignacio, J., Jordan, S. J., Kiyota, N., Buettner, M., Engesser, D., Canotilho, R., Ioannidis, G., Husson, O., Gama, R. R., Fanetti, G., Moss, L., … Sykiotis, G. (2023). International phase IV field study for the reliability and validity of the european organisation for research and treatment of cancer thyroid cancer module EORTC QLQ-THY34. Thyroid: Official Journal of the American Thyroid Association, 33(9), 1078–1089. https://doi.org/10.1089/thy.2023.0221CrossRefPubMed

30.

Diamond-Rossi, S. A., Jonklaas, J., Jensen, R. E., Kuo, C., Stearns, S., Esposito, G., Davidson, B. J., Luta, G., Bloom, G., & Graves, K. D. (2020). Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer. Journal of Cancer Survivorship: Research and Practice, 14(6), 847–857. https://doi.org/10.1007/s11764-020-00897-5CrossRefPubMed

31.

Willis, G., Lawrence, D., Thompson, F., Kudela, M., Levin, K., & Miller, K. (2005). The use of cognitive interviewing to evaluate translated survey questions: Lessons learned. Conference of the Federal Committee on Statistical Methodology, Arlington, VA.

32.

Lenzner, T., Hadler, P., & Neuert, C. (2023). An experimental test of the effectiveness of cognitive interviewing in pretesting questionnaires. Quality & Quantity, 57(4), 3199–3217. https://doi.org/10.1007/s11135-022-01489-4CrossRef

33.

Klein Hesselink, E. N., Brouwers, A. H., de Jong, J. R., van der Horst-Schrivers, A. N. A., Coppes, R. P., Lefrandt, J. D., Jager, P. L., Vissink, A., & Links, T. P. (2016). Effects of radioiodine treatment on salivary gland function in patients with differentiated thyroid carcinoma: A prospective study. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 57(11), 1685–1691. https://doi.org/10.2967/jnumed.115.169888CrossRefPubMed

34.

Thomson, W. M., & Williams, S. M. (2000). Further testing of the xerostomia inventory. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, 89(1), 46–50. https://doi.org/10.1016/s1079-2104(00)80013-xCrossRefPubMed

35.

Peterman, A. H., Fitchett, G., Brady, M. J., Hernandez, L., & Cella, D. (2002). Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy–Spiritual Well-being Scale (FACIT-Sp). Annals of Behavioral Medicine: A Publication of the Society of Behavioral Medicine, 24(1), 49–58. https://doi.org/10.1207/S15324796ABM2401_06CrossRefPubMed

36.

Costello, A. B., & Osborne, J. (2019). Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. Practical assessment, research, and evaluation, 10(1), 7. https://doi.org/10.7275/JYJ1-4868CrossRef

37.

Williams, B., Onsman, A., & Brown, T. (2010). Exploratory Factor Analysis: A Five-Step Guide for Novices. Australasian Journal of Paramedicine, 8, 1–13. https://doi.org/10.33151/ajp.8.3.93CrossRef

38.

Preacher, K. J., & MacCallum, R. C. (2002). Exploratory factor analysis in behavior genetics research: Factor recovery with small sample sizes. Behavior Genetics, 32, 153–161.CrossRefPubMed

39.

Velicer, W. F., & Fava, J. L. (1998). Affects of variable and subject sampling on factor pattern recovery. Psychological Methods, 3(2), 231.CrossRef

40.

Henson, R. K., & Roberts, J. K. (2006). Use of exploratory factor analysis in published research: Common errors and some comment on improved practice. Educational and Psychological Measurement, 66(3), 393–416.CrossRef

41.

Kline, P. (1979). Psychometrics and psychology. Academic Press.

42.

Singer, M. C., Marchal, F., Angelos, P., Bernet, V., Boucai, L., Buchholzer, S., Burkey, B., Eisele, D., Erkul, E., Faure, F., Freitag, S. K., Gillespie, M. B., Harrell, R. M., Hartl, D., Haymart, M., Leffert, J., Mandel, S., Miller, B. S., Morris, J., Pearce, E. N., Rahmati, R., Ryan, W. R., Schaitkin, B., Schlumberger, M., Stack, B. C., Van Nostrand, D., Wong, K. K., & Randolph, G. (2020). Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. In Head Neck (2020/08/19 ed.). https://www.ncbi.nlm.nih.gov/pubmed/32812307

43.

Mandel, S. J., & Mandel, L. (2003). Radioactive iodine and the salivary glands. Thyroid: Official Journal of the American Thyroid Association, 13(3), 265–271. https://doi.org/10.1089/105072503321582060CrossRefPubMed

44.

Morgenstern, K. E., Vadysirisack, D. D., Zhang, Z., Cahill, K. V., Foster, J. A., Burns, J. A., Kloos, R. T., & Jhiang, S. M. (2005). Expression of sodium iodide symporter in the lacrimal drainage system: Implication for the mechanism underlying nasolacrimal duct obstruction in I131-treated patients. Ophthalmic Plastic & Reconstructive Surgery, 21(5), 337. https://doi.org/10.1097/01.iop.0000179369.75569.a8CrossRef

45.

Buchholzer, S., Faure, F., Tcheremissinoff, L., Herrmann, F. R., Lombardi, T., Ng, S.-K., Lopez, J.-M., Borner, U., Witt, R. L., Irvine, R., Abboud, O., Cernea, C. R., Ghan, S., Matsunobu, T., Ahmad, Z., Morton, R., Anicin, A., Magdy, E. A., Al Abri, R., … Marchal, F. (2022). Novel multidisciplinary salivary gland society (MSGS) questionnaire: An international consensus. The Laryngoscope, 132(2), 322–331. https://doi.org/10.1002/lary.29731CrossRefPubMed

46.

Floyd, F. J., & Widaman, K. F. (1995). Factor analysis in the development and refinement of clinical assessment instruments. Psychological Assessment, 7(3), 286–299. https://doi.org/10.1037/1040-3590.7.3.286CrossRef

Titel: Salivary, lacrimal and nasal (SALANS) measure to assess side effects following radioactive iodine treatment: development, psychometric properties, and factor structure
Auteurs: Jacqueline Jonklaas
Alaina L. Carr
George Luta
Chenlu Yu
Roxanne E. Jensen
Emma Reasner
Justin Winslow
Charlene C. Kuo
Bruce J. Davidson
Giuseppe Esposito
Gary Bloom
Samantha A. Diamond-Rossi
Kristi D. Graves
Publicatiedatum: 20-05-2024
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 7/2024
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-024-03684-2

Andere artikelen Uitgave 7/2024

Quality of life in a high-risk group of elderly primary care patients: characteristics and potential for improvement

Open Access

What facets of physical function are most important to adults diagnosed with cancer?

Influence of frailty status on the health-related quality of life in older patients with chronic low back pain: a retrospective observational study

An influence of menopausal symptoms on mental health, emotion perception, and quality of life: a multi-faceted approach

Facets of physical function assessed by patient-reported outcome measures in oncology research

Health-related quality of life in Parkinson’s disease: systematic review and meta-analysis of EuroQol (EQ-5D) utility scores

Review